Sentences with phrase «us biotechnology companies»

Shares in Perth - based biotechnology company Orthocell have risen slightly on the back of it striking a partnership with leading Swedish medical technology company Bonesupport.

That's the plan for Intrommune, a new New York - based biotechnology company that recently acquired the rights to license the toothpaste technology they intend to apply to food allergies.

• Nuritas, a biotechnology company focused on the discovery and use of bioactive peptides through artificial intelligence and genomics, raised $ 20 million in Series A funding.

• IDEAYA Biosciences, Inc., an oncology - focused biotechnology company, raised $ 94 million in Series B funding.

It's risky to invest in a biotechnology company.

• Myonexus Therapeutics, a New Albany, Oh. - based clinical - stage biotechnology company developing transformative gene therapies for limb - girdle muscular dystrophies, raised $ 2.5 million in seed funding.

If you ask Bill Doyle, the executive chairman of the board of Novocure, the two - pronged strategy for expanding his tumor - tackling biotechnology company is «relatively simple.»

• Bonti, a Newport Beach, Calif. clinical - stage biotechnology company, raised $ 11.7 million in Series B funding.

Janet Yellen warned that biotechnology companies may be over-valued.

Biotechnology company Imugene said it has achieved «one of its biggest regulatory milestones» with a licence for the limited release of its poultry productivity enhancer (PPE).

Perth - based biotechnology company Metavone hopes to list on the ASX next month after raising up to $ 5 million from investors in an initial public offering.

Editas, along with other biotechnology companies, want to use CRISPR as a way to potentially create some.

Starting with some well - timed local property investments that cemented his wealth, Li built a business empire that included retail, energy, ports, telecommunications, media and biotechnology companies worldwide.

• Akouos, a Brookline, Mass. - based biotechnology company focused on restoring and preserving hearing, raised $ 7.5 million in seed funding.

Dr. Peter H. Diamandis, chairman of the X Prize Foundation, and Dr. Robert Hariri, founder and chief scientific officer of cell therapy operations at the biotechnology company Celgene, are both co-founders.

Overall, WA is believed to have 24 biotechnology companies representing 13 per cent of Australia's 185 dedicated biotechnology companies.

• Semma Therapeutics, a Cambridge, Mass. - based biotechnology company focused on the development of novel regenerative medicines, raised $ 114 million in Series B funding.

The French drugmaker is nearing a deal to acquire biotechnology company Bioverativ for $ 105 a share.

Queensland has 11 per cent of the national total of biotechnology companies.

• Apexian Pharmaceuticals, an Indiana - based clinical stage biotechnology company, raised Series A funding of an undisclosed amount.

Venture - capital funding increased slightly in the second quarter from the previous quarter, with software and biotechnology companies leading the pack, according to a report released today.

A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

• Recursion Pharmaceuticals, a Salt Lake City, Utah - based biotechnology company that combines biological science with artificial intelligence, raised $ 60 million in Series B funding.

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology - focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult - to - treat cancers.

Amgen, the biggest independent biotechnology company in the world, said it bought back $ 10.7 billion worth of stock last quarter — seven times bigger than its 2017 buyback and an 8.5 percent decrease in its total share count.

Eagle's Sassouni pointed out that since the big drug companies are losing billions of dollars every year to generic versions and have little to spend on their own research and development, they are looking to buy smaller biotechnology companies that are developing their own products.

• Exonics Therapeutics, Inc, a Boston - based biotechnology company focused on developing SingleCut CRISPR technology to repair mutations causing Duchenne muscular dystrophy and other neuromuscular diseases, raised $ 40 million in Series A funding.

Arafura Resources Ltd has been awarded a $ 3.3 million federal government grant for its NT rare earths - uranium project while biotechnology company Imugene Ltd has secured an $ 880,000 grant to produce and test bird flu vaccines on chickens.

Perth biotechnology company Imugene Ltd has received notice of grant for patent protection for its Porcine Adenoviral Delivery Vector technology in the United States of America, the company has announced.

WA - based biotechnology company Imugene Ltd has won exclusive distribution rights for its porcine adenoviral vector delivery system, after success in a hearing administered by the US patent office.

Celgene Corp. agreed to buy blood - disease biotechnology company Impact Biomedicines for as much as $ 7 billion.

New York, NY — Goldman Sachs, in an April report to clients, addressed an ethical conundrum facing pharmaceutical and biotechnology companies in regard to futuristic...

Dr. Michael West: The CEO of BioTime, Inc., a leading clinical - stage biotechnology company in the field of regenerative medicine.

The city approved a payroll tax break for biotechnology companies seven years ago, and Ms. Matz said it had helped attract dozens of biotech start - ups.

Blockchain companies nonetheless are among the February stocks to watch, along with emerging biotechnology companies and some beaten down stocks that are attracting new interest.

The takeover interest in Tesaro underscores the pharmaceutical industry's strong appetite for the acquisition of biotechnology companies with promising medicines under development in lucrative sectors such as cancer treatment.

The U.S. Securities and Exchange Commission has charged the Columbia biotechnology company Osiris Therapeutics and four of its former executives with accounting fraud.

The biotechnology company lowered its full - year Otezla sales forecast to $ 1.25 billion, from a range of $ 1.5 billion to $ 1.7 billion.

Derek's primary responsibility at RA Capital is to conduct due diligence on biotechnology companies.

Ryan's primary responsibility at RA Capital is to is to conduct due diligence on biotechnology companies.

LONDON Europe's biggest biotechnology company, Denmark's Genmab, expects some delays to regional drug approvals as the European Medicines Agency is uprooted from London to Amsterdam.

COPENHAGEN, April 10 Genmab plans to own a bigger share of drugs in its early - stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson.

Neta's primary responsibility at RA Capital is to conduct due diligence on biotechnology companies.

Jake's primary responsibility at RA Capital is to conduct due diligence on biotechnology companies.

BGV III is now one of the largest funds focused on seed investments in European biotechnology companies.

IDEAYA Biosciences, Inc., an oncology - focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines and immuno - oncology therapies, announced today the successful completion of a $ 94 million crossover Series B financing.

Cambridge, MA — February 6, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug application (IND) for the company's lead program, light - activated AU - 011 in ocular melanoma (OM).

Bala Cynwyd, PA — January 31, 2017 — Chondrial Therapeutics, Inc., an emerging biotechnology company focused on the treatment of rare mitochondrial diseases, announced today that it has secured up to $ 22.6 million in Series A financing led by Deerfield Management and has appointed Carole Ben - Maimon, MD, as the company's president and chief executive officer.

Cambridge, MA — December 21, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it closed a $ 30 million Series C financing.

Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.